Table 1. Characteristics of indications in the study sample from China.
| Indications supported by randomized controlled trials (N = 76) | Number | Percent |
|---|---|---|
| Cancer site | ||
| Blood | 15 | 20 |
| Lung | 15 | 20 |
| Breast | 11 | 14 |
| Colorectal | 5 | 7 |
| Renal | 5 | 7 |
| Other | 25 | 33 |
| Domestically developed | ||
| Yes | 19 | 25 |
| No | 57 | 75 |
| Priority review | ||
| Yes | 37 | 49 |
| No | 39 | 51 |
| Administration route | ||
| Intravenous | 23 | 30 |
| Oral | 53 | 70 |
| First-line therapy | ||
| Yes | 30 | 39 |
| No | 46 | 61 |
| Blind | ||
| Yes | 38 | 50 |
| No | 38 | 50 |
| Comparator | ||
| Placebo | 25 | 33 |
| Active | 51 | 67 |
| Year of approval | ||
| Before 2017 | 29 | 38 |
| 2017 and beyond | 47 | 62 |
| Indications supported by single-arm clinical trials (N = 27) | Number | Percent |
| Cancer site | ||
| Hematological | 14 | 52 |
| Non-hematological | 13 | 48 |
| Domestically developed | ||
| Yes | 18 | 67 |
| No | 9 | 33 |
| Conditional approval | ||
| Yes | 19 | 70 |
| No | 8 | 30 |
| Administration route | ||
| Intravenous | 13 | 48 |
| Oral | 14 | 52 |
| First-line therapy | ||
| Yes | 4 | 15 |
| No | 23 | 85 |
| Year of approval | ||
| Before 2017 | 4 | 15 |
| 2017 and beyond | 23 | 85 |